Rhabdomyosarcoma clinical trials report from VPA Research provides comprehensive analysis and trends in global Rhabdomyosarcoma disease clinical trials. The research work analyzes the evolution of Rhabdomyosarcoma clinical trial trends across countries and regions.
The report focuses on drugs and therapies being evaluated for Rhabdomyosarcoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Rhabdomyosarcoma clinical trials.
Scope of the Report- - Number of Rhabdomyosarcoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas - Trial information by Phase and Subjects recruited - Trial information by status, type, sponsor type - Drugs used for treatment of Rhabdomyosarcoma - Both observational and interventional trials analyzed - Success rates of trials are analyzed - Trends in enrollment over the past ten years identified - Leading sponsors of Rhabdomyosarcoma clinical trials worldwide are listed
Reasons to Buy - Track competition and design competitive advantages - Identify right partners to associate with for further research - Evaluate potential opportunities available in further clinical trials of the disease - Formulate business development strategies through success rates of clinical trials - Identify quick markets for recruiting subjects based on trials count by each market
Rhabdomyosarcoma is one of the most common types of soft tissue sarcoma found both in children and young adults. It can originate from any part of the body with muscle tissues like skeletal or smooth muscles. Common site are arms and legs, reproductive organs, head and neck.
Globally, 40 countries participated in clinical trials. Of this, the US leads the list of countries with a participation in 139 trials, Canada (29 trials) and Germany (25 trials).
Some of the key drugs approved for Rhabdomyosarcoma by FDA include- - Actinomycin (Dactinomycin) - Vincristine (Leurocristine Sulfate/ LCR/VCR) - Cyclophosphamide (CPM/CTX/CYT)
Our reports have been used by over 10K customers, including:
Healthcare Contract Research Organization Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical, Clinical), By Service (Clinical Monitoring, Data Management), By Region, And Segment Forecasts, 2021 - 2028
Healthcare Contract Research Organization Market Growth & Trends
The analyst presents post–COVID-19 growth opportunities and strategic imperatives for the global decentralized clinical trials (DCT) market, covering the market’s maturity, key participants, adoption drivers and restraints, and recent mergers and acquisitions. The report identifies initiatives by major global contract research organizations...
Hepatitis C (Infectious Disease) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Drugs In Development, 2021, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape. Hepatitis C is a contagious viral...
The ePRO, ePatient Diaries, and eCOA market in North America is expected to grow from US$ 607.2 million in 2021 to US$ 1,640.6 million by 2028; it is estimated to grow at a CAGR of 15.3% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. As per the...
Essential Thrombocythemia (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Drugs In Development, 2021, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape.Essential thrombocythemia...
Histone Deacetylase 1 (HDAC1 or EC 126.96.36.199) - Drugs In Development, 2021 Summary According to the recently published report ’Histone Deacetylase 1 - Drugs In Development, 2021’; Histone Deacetylase 1 (HDAC1 or EC 188.8.131.52) pipeline Target constitutes close to 39 molecules. Out of which approximately...
The ePRO, ePatient Diaries, and eCOA market in Europe is expected to grow from US$ 447.8 million in 2021 to US$ 1,184.3 million by 2028; it is estimated to grow at a CAGR of 14.9% from 2021 to 2028. As per the data provided by Clinicaltrials.gov, 2016 has been a big one for clinical research. There were around 366 thousand clinical studies...
The ePRO, ePatient diaries, and eCOA market in Asia Pacific is expected to grow from US$ 348.8 million in 2021 to US$ 964.2 million by 2028; it is estimated to grow at a CAGR of 15.6% from 2021 to 2028. Healthcare systems are experiencing a rise in consumer engagement worldwide. In developing countries, health care systems are becoming more...
The ePRO, ePatient Diaries, and eCOA market in Middle East and Africa is expected to grow from US$ 48.4 million in 2021 to US$ 112.3 million by 2028; it is estimated to grow at a CAGR of 12.8% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. Mobile-enabled...
Health Provider Density
Medical Technology Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.